🧬Unveiling Our New Logo: A Symbol of Hope and Innovation🧬 Introducing our brand new logo symbolizes our unwavering commitment to progress and excellence in the healthcare industry. This refreshed identity embodies our core values and aspirations for the future. Our new logo boats simplified hexagons, representing the molecular structure of DNA bases. The merging of two hexagons symbolizes the DNA double helix and the concept of "infinite hope." The vibrant blue hue conveys professionalism, innovation, and a deep sense of care. #ACTGenomics #genomics #personalizedmedicine #precisionmedicine #futureofhealthcare
About us
ACT Genomics is a world-leading genomic test solution provider. Our mission is to make personalized medicine accessible to all. We offer precision medicine services globally. Combining tumor biology, cancer genomics, and bioinformatics experts to provide treatment guidelines for solid tumors, relapse, and drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. We are dedicated to turning every cancer patient's genetic information into actionable resolutions through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings. Our NGS platform, coupled with sophisticated bioinformatics tools and curated proprietary databases, enables us to deliver reliable results for clinical and research purposes, and our data visualization technologies make the scientific results easily understandable for everyone. Our clinical services include cancer prevention, early detection, treatment selection, and disease monitoring. Our genomic assays offer comprehensive cancer genomic profiling and treatment options for patients with cancer and provide insights into biomarker discovery and patient stratification for clinical trials.
- Website
-
https://www.actgenomics.com
External link for ACT Genomics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Taipei
- Type
- Privately Held
- Founded
- 2014
- Specialties
- cancer biology, molecular information, next generation sequencing, bioinformatics, precision medicine, cancer drug development, oncology, and cancer genomics sequencing
Locations
-
Primary
Get directions
3F ., No.345, Xinhu 2nd Rd., Neihu Dist
Taipei City, Taiwan
Taipei, 11494, TW
-
Get directions
10 Anson Road, #05-01 International Plaza
Singapore, Singapore 089058, SG
-
Get directions
No.15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok. NT
Units 803 – 807, 8F, Building 15W
Hong Kong, Pak Shek Kok. NT Units 803 – 807, HK
-
Get directions
No.4, 4/5 Unit 1503, Unit 1509, Central Tower, 15/F, Ratchadamri Road, Pathumwan
Bangkok, TH
Employees at ACT Genomics
Updates
-
Our Chief Scientific Officer and Co-founder, Dr. Hua Chien Chen will join #ASGH as the speaker for the discussion of "Seeing the Unseen - Precision Medicine with Genomic Insight." Don't miss out: https://smpl.is/94nw9
-
-
𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗜𝗻 𝗔𝗰𝘁𝗶𝗼𝗻 Discuss the application and latest trend with ACT Genomics in #ASCO 2024. Submit the survey to book a time with our representatives here: https://smpl.is/92066 We can't wait to see you on-site!
-
-
Head and neck cancer (#HNC) remains a significant health concern, but the landscape is shifting thanks to precision medicine. This revolutionary approach moves beyond a "one-size-fits-all" strategy by analyzing the unique genetic makeup of your tumor to tailor treatment plans. Here's how #PrecisionMedicine is transforming HNC treatment: https://smpl.is/919vn #CancerAwarenessMonth
-
#HeadandNeckCancer (HNC) can be really complex! While it may sound severe, it's important to remember that significant progress is being made, especially with the rise of #PersonalizedMedicine. Here's a breakdown of it improves the treatment planning. Discover more: https://smpl.is/90bkz #CancerAwarenessMonth
-
-
Join us in understanding why it is important to participate in the #FoCR #HRDHarmonization project. 🔬 "This collaborative effort aims to unravel the inconsistencies in HRD testing, paving the way for more accurate patient identification and improved treatment outcomes." Finds out more: https://smpl.is/8xjxp
-
-
The #ACTNews blog dives deep into cutting-edge cancer research this week! Here are 3 intriguing articles you shouldn't miss: 1. Post-Op ctDNA Testing for Low-Risk Colon Cancer: Worthwhile? 2. Quadruple Therapy for Advanced NSCLC: Promising Results! 3. Genetic Testing Gaps in mCRPC: A Real-World Look. Head over to the our blog for more #PrecisionMedicine news: https://smpl.is/8wn5d
-
It's #ColorectalCancer (CRC) awareness month! While it remains a significant health concern, advancements in #PrecisionMedicine offer a ray of hope. The treatment approach moves beyond a "one-size-fits-all" strategy by analyzing your tumor's unique genetic makeup to tailor treatment plans. Here's what you should know about colorectal cancer and how genomic testing empowers precision medicine: https://smpl.is/8w7z6
-
-
What is the FoCR HRD harmonization project? What is the purpose of this project? Join us in navigating the Maze: Friends of Cancer Research (FoCR) Tackles HRD Inconsistencies in Cancer Care. Find out more about this project: https://lnkd.in/gtxQCi8P
What is the FoCR HRD harmonization project? What is the purpose of this project? | ACT Genomics
actgenomics.com
-
Being part of the Homologous Recombination Deficiency (HRD) Harmonization Project is an honor! Join us in understanding differences in determining HRD status and bringing consistency across various methods.
Homologous Recombination Deficiency (HRD) is a complex biomarker that can help identify patients likely to respond to certain therapies. Friends of Cancer Research's HRD Harmonization Project is a unique research partnership designed to: - find alignment among different assays that measure HRD - support its use as a biomarker in clinical research and care - serve as a foundational approach to inform future areas of research We worked with leading diagnostic test developers and other key stakeholders to evaluate a common set of tumor samples. The project assessed variability across 17 different HRD tests and identified opportunities for future alignment. Thank you to all of our project partners! Project Info: https://lnkd.in/gKz97RXP Initial Findings: https://lnkd.in/g_e4WmBf Public Meeting Recording: https://lnkd.in/gbXQEDbd #biomarker #cancer #research
-